Biological Markers
Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers
epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics
ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals
ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development
Recent Developments in Immune Profiling for Early Immuno-Oncology Trials
immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine
Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results
Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment
NewAmsterdam Reports Cholesterol Drug Obicetrapib May Slow Alzheimer’s Biomarker Buildup
NewAmsterdam Pharma; obicetrapib; cholesterol ester transfer protein inhibitor (CETP); Alzheimer’s disease biomarkers; p-tau217; ApoE4; BROADWAY trial; Phase 3
Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202
Regenxbio; DMD; Duchenne muscular dystrophy; RGX-202; gene therapy; AFFINITY DUCHENNE trial; clinical trial; microdystrophin; biomarker; phase I/II; functional data
Precision Medicine’s Next Frontier: Unlocking the Power of Biospecimens
precision medicine; biospecimens; multi-omics; drug development; biobanking; personalized medicine; biomarkers; spatial transcriptomics; cancer genomics
Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI
Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration
Revolutions KRAS drugs appear competitive in several lung cancer settings
KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines
Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug
Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval